17 results on '"Kanevsky, Estella"'
Search Results
2. Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus With or Without Heart Failure or Kidney Dysfunction: Observations From the SAVOR-TIMI 53 Trial
- Author
-
Bergmark, Brian A., Bhatt, Deepak L., McGuire, Darren K., Cahn, Avivit, Mosenzon, Ofri, Steg, Ph. Gabriel, Im, KyungAh, Kanevsky, Estella, Gurmu, Yared, Raz, Itamar, Braunwald, Eugene, and Scirica, Benjamin M.
- Published
- 2019
- Full Text
- View/download PDF
3. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)
- Author
-
Bonaca, Marc P., Nault, Patrice, Giugliano, Robert P., Keech, Anthony C., Pineda, Armando Lira, Kanevsky, Estella, Kuder, Julia, Murphy, Sabina A., Jukema, J. Wouter, Lewis, Basil S., Tokgozoglu, Lale, Somaratne, Ransi, Sever, Peter S., Pedersen, Terje R., and Sabatine, Marc S.
- Published
- 2018
- Full Text
- View/download PDF
4. Abstract 20183: Atherothrombotic Risk Stratification and Magnitude of Benefit of Evolocumab in FOURIER
- Author
-
Bohula, Erin A, Morrow, David A, Pedersen, Terje R, Kanevsky, Estella, Murphy, Sabina A, Giugliano, Robert P, Sever, Peter S, Keech, Anthony C, and Sabatine, Marc S
- Published
- 2017
5. Long-term safety and efficacy of breast biopsy markers in clinical practice
- Author
-
Smith, Sharon, primary, Taylor, Clayton R., additional, Kanevsky, Estella, additional, Povoski, Stephen P., additional, and Hawley, Jeffrey R., additional
- Published
- 2020
- Full Text
- View/download PDF
6. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk
- Author
-
O'Donoghue, Michelle L., Fazio, Sergio, Giugliano, Robert P., Stroes, Erik S. G., Kanevsky, Estella, Gouni-Berthold, Ioanna, Im, KyungAh, Lira Pineda, Armando, Wasserman, Scott M., Češka, Richard, Ezhov, Marat V., Jukema, J. Wouter, Jensen, Henrik K., Tokgözoğlu, S. Lale, Mach, François, Huber, Kurt, Sever, Peter S., Keech, Anthony C., Pedersen, Terje R., Sabatine, Marc S., Experimental Vascular Medicine, Vascular Medicine, and ACS - Atherosclerosis & ischemic syndromes
- Abstract
BACKGROUND: Lipoprotein(a) [Lp(a)] may play a causal role in atherosclerosis. PCSK9 (proprotein convertase subtilisin/kexin 9) inhibitors have been shown to significantly reduce plasma Lp(a) concentration. However, the relationship between Lp(a) levels, PCSK9 inhibition, and cardiovascular risk reduction remains undefined. METHODS: Lp(a) was measured in 25 096 patients in the FOURIER trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk), a randomized trial of evolocumab versus placebo in patients with established atherosclerotic cardiovascular disease (median follow-up, 2.2 years). Cox models were used to assess the independent prognostic value of Lp(a) and the efficacy of evolocumab for coronary risk reduction by baseline Lp(a) concentration. RESULTS: The median (interquartile range) baseline Lp(a) concentration was 37 (13-165) nmol/L. In the placebo arm, patients with baseline Lp(a) in the highest quartile had a higher risk of coronary heart disease death, myocardial infarction, or urgent revascularization (adjusted hazard ratio quartile 4: quartile 1, 1.22; 95% CI, 1.01-1.48) independent of low-density lipoprotein cholesterol. At 48 weeks, evolocumab significantly reduced Lp(a) by a median (interquartile range) of 26.9% (6.2%-46.7%). The percent change in Lp(a) and low-density lipoprotein cholesterol at 48 weeks in patients taking evolocumab was moderately positively correlated ( r=0.37; 95% CI, 0.36-0.39; Pmedian, and by 7% (hazard ratio, 0.93; 95% CI, 0.80-1.08; P interaction=0.07) in those ≤median. Coupled with the higher baseline risk, the absolute risk reductions, and number needed to treat over 3 years were 2.49% and 40 versus 0.95% and 105, respectively. CONCLUSIONS: Higher levels of Lp(a) are associated with an increased risk of cardiovascular events in patients with established cardiovascular disease irrespective of low-density lipoprotein cholesterol. Evolocumab significantly reduced Lp(a) levels, and patients with higher baseline Lp(a) levels experienced greater absolute reductions in Lp(a) and tended to derive greater coronary benefit from PCSK9 inhibition. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifier: NCT01764633.
- Published
- 2019
7. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk
- Author
-
O’Donoghue, Michelle L., primary, Fazio, Sergio, additional, Giugliano, Robert P., additional, Stroes, Erik S.G., additional, Kanevsky, Estella, additional, Gouni-Berthold, Ioanna, additional, Im, KyungAh, additional, Lira Pineda, Armando, additional, Wasserman, Scott M., additional, Češka, Richard, additional, Ezhov, Marat V., additional, Jukema, J. Wouter, additional, Jensen, Henrik K., additional, Tokgözoğlu, S. Lale, additional, Mach, François, additional, Huber, Kurt, additional, Sever, Peter S., additional, Keech, Anthony C., additional, Pedersen, Terje R., additional, and Sabatine, Marc S., additional
- Published
- 2019
- Full Text
- View/download PDF
8. Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial
- Author
-
Bohula, Erin A, primary, Scirica, Benjamin M, additional, Inzucchi, Silvio E, additional, McGuire, Darren K, additional, Keech, Anthony C, additional, Smith, Steven R, additional, Kanevsky, Estella, additional, Murphy, Sabina A, additional, Leiter, Lawrence A, additional, Dwyer, Jamie P, additional, Corbalan, Ramon, additional, Hamm, Christian, additional, Kaplan, Lee, additional, Nicolau, Jose Carlos, additional, Ophuis, Ton Oude, additional, Ray, Kausik K, additional, Ruda, Mikhail, additional, Spinar, Jindrich, additional, Patel, Tushar, additional, Miao, Wenfeng, additional, Perdomo, Carlos, additional, Francis, Bruce, additional, Dhadda, Shobha, additional, Bonaca, Marc P, additional, Ruff, Christian T, additional, Sabatine, Marc S, additional, Wiviott, Stephen D, additional, Inzucchi, Silvio, additional, Keech, Anthony, additional, Satlin, Andrew, additional, Brown, Conville, additional, Budaj, Andrzej, additional, Dwyer, Jamie, additional, Garcia-Castillo, Armando, additional, Gupta, Milan, additional, Oude Ophuis, Ton, additional, Ray, Kauski, additional, Weissman, Neil, additional, White, Harvey D, additional, Amerena, J, additional, Arstall, M, additional, Colquhoun, D, additional, Jayasinghe, R, additional, Lee, A, additional, Lehman, R, additional, Moses, R, additional, Proietto, J, additional, Purnell, P, additional, Waites, J, additional, Blombery, P, additional, Cross, D, additional, Worthley, M, additional, d'Emden, M, additional, Selvanayagam, J, additional, Oqueli, RE, additional, Whelan, A, additional, Garrahy, P, additional, de Looze, F, additional, Ninio, D, additional, Horowitz, J, additional, William, M, additional, Suranyi, M, additional, Wittert, G, additional, Le May, M, additional, Pandey, AS, additional, Vizel, S, additional, Labonte, R, additional, Beaudry, Y, additional, Fortin, C, additional, Bell, A, additional, Kouz, S, additional, St-Amour, É, additional, Bata, I, additional, St Maurice, F, additional, Chehayeb, R, additional, Constance, C, additional, Wong, G, additional, Hess, A, additional, Liutkus, J, additional, Poirier, P, additional, Teitelbaum, I, additional, Berlingieri, J, additional, Cha, J, additional, Hartleib, M, additional, Heffernan, M, additional, Twum-Barima, D, additional, Pandith, V, additional, Aronson, R, additional, Goldenberg, R, additional, Ajala, B, additional, Jain, A, additional, Ross, S, additional, Bajaj, H, additional, Khandwala, H, additional, Yared, Z, additional, Gupta, N, additional, Bédard, J, additional, Wharton, S, additional, Blouin, F, additional, Savard, D, additional, Shukla, D, additional, Cobos, J, additional, Godoy, G, additional, Perez, L, additional, Pincetti, C, additional, Saavedra Guajardo, V, additional, Varleta, P, additional, Conejeros, C, additional, Lanas, F, additional, Bayram Llamas, E, additional, Cardona Muñoz, E, additional, Garcia, R, additional, Garza Ruiz, J, additional, Llamas Esperon, G, additional, Lopez Rosas, E, additional, Melendez Mier, G, additional, Ramos, G, additional, Hart, H, additional, Scott, D, additional, Ternouth, I, additional, Benatar, J, additional, Elliott, J, additional, Cutfield, R, additional, Manning, P, additional, Williams, M, additional, Ferrier, K, additional, Scott, R, additional, Wilson, S, additional, Leikis, R, additional, Nirmalaraj, BK, additional, Krzyżagórska, E, additional, Miękus, P, additional, Bronisz, M, additional, Mirek-Bryniarska, E, additional, Łanda, K, additional, Stasiewski, A, additional, Żechowicz, T, additional, Zytkiewicz-Jaruga, D, additional, Korecki, J, additional, Ogórek, M, additional, Pawłowicz, L, additional, Piepiorka, M, additional, Skierkowska, J, additional, Stankiewicz, A, additional, Szyprowska, E, additional, Witek, R, additional, Bochenek, A, additional, Kończakowski, P, additional, Wojnowski, Ł, additional, Wujkowski, M, additional, Cymerman, K, additional, Korzeniak, R, additional, Mąder, P, additional, Mikłaszewicz, B, additional, Stachlewski, P, additional, Goch, A, additional, Pomiećko, W, additional, Skórski, M, additional, Romanowski, L, additional, Jusiak, K, additional, Laskowska-Derlaga, E, additional, Bijata-Bronisz, R, additional, Kaźmierczak, J, additional, Goldberg, R, additional, Henderson, D, additional, Korban, E, additional, Rohr, K, additional, Claxton, E, additional, Weiss, R, additional, Angiolillo, D, additional, Boccalandro, F, additional, Chu, K, additional, Thorn, E, additional, Randhawa, P, additional, Singh, N, additional, Bittar, G, additional, Guarnieri, T, additional, Saeed, S, additional, Sharma, S, additional, Shepard, M, additional, French, W, additional, Desai, P, additional, Bernstein, R, additional, Rogers, W, additional, Singal, R, additional, Schneider, R, additional, Shanes, J, additional, Ong, S, additional, Condit, J, additional, Donahoe, S, additional, Brill, D, additional, Einhorn, D, additional, Ebrahimi, R, additional, Labroo, A, additional, Graf, R, additional, Scott, J, additional, Hoekstra, J, additional, Jetty, P, additional, Luckasen, G, additional, O'Donnell, P, additional, Gonte, W, additional, Pomposini, D, additional, Quadrel, M, additional, Koren, M, additional, Schlager, D, additional, Schramm, E, additional, Singal, D, additional, Lupovitch, S, additional, Soni, A, additional, Seigel, P, additional, Roberts, J, additional, Soufer, J, additional, Reza, S, additional, Quinlan, E, additional, Moretto, T, additional, First, B, additional, Khan, M, additional, Chilka, S, additional, Colfer, H, additional, Teklinski, A, additional, Wallace-Wilding, K, additional, Ellison, H, additional, Muse, D, additional, Aronoff, S, additional, Higgins, A, additional, Patel, S, additional, Elinoff, V, additional, Karim, A, additional, Awasty, V, additional, Chuang, R, additional, Roseman, H, additional, Dugano-Daphnis, P, additional, Albert, M, additional, Sheikh, K, additional, Bays, H, additional, Kaster, S, additional, Goldstein, M, additional, Rubino, D, additional, Calatayud, G, additional, Snyder, H, additional, Williams, T, additional, Hershon, K, additional, Hagan, M, additional, Isserman, S, additional, Kahn, B, additional, Anderson, J, additional, Gimness, MP, additional, Raisinghani, A, additional, Christina, M, additional, Raikhel, M, additional, Gillespie, E, additional, Portnay, E, additional, Heiman, M, additional, Qureshi, M, additional, Lee, J, additional, Blonder, R, additional, Cucher, F, additional, Miller, G, additional, Kotlaba, D, additional, Cornett, G, additional, Beavins, J, additional, Augenbraun, C, additional, Reinhardt, S, additional, Bartkowiak, A, additional, Salacata, A, additional, Blevins, T, additional, Benjamin, S, additional, Diener, J, additional, George, W, additional, Barker, B, additional, Richwine, R, additional, Baldari, D, additional, Alfieri, A, additional, Barreto, A, additional, Zhang, L, additional, Shah, R, additional, Hendrix, E, additional, Subramaniyam, V, additional, Hurley, S, additional, Lillestol, M, additional, O'Donoghue, M, additional, Shayani, S, additional, Ryan, E, additional, Call, R, additional, Zemel, L, additional, Chang, A, additional, Kivitz, A, additional, Freyne, B, additional, Bland, V, additional, Shore, K, additional, Mostel, E, additional, Uzoaga, E, additional, Andrawis, N, additional, Gabra, N, additional, Ghitis, A, additional, Sabatino, K, additional, Browder, D, additional, Varma, S, additional, Smith, S, additional, Fink, R, additional, Aycock, GR, additional, Doty, WD, additional, Alfonso, T, additional, Eshaghian, S, additional, Karlsberg, R, additional, Zarich, S, additional, Landau, C, additional, McKenzie, M, additional, Krause, R, additional, Davis, W, additional, Haddad, T, additional, Voyce, S, additional, Alford, C, additional, LeDoux, J, additional, O'Dea, D, additional, Park, J, additional, Aroda, V, additional, Getaneh, A, additional, Graham, B, additional, Bhagwat, R, additional, Korn, D, additional, Ruoff, G, additional, Wiseman, A, additional, Lieber, I, additional, Fialkow, J, additional, Gonzalez-Campoy, JM, additional, Bayron, C, additional, Bertolet, B, additional, Lash, J, additional, Gerrish, C, additional, Robertson, D, additional, Rosenfeld, J, additional, Seidner, M, additional, Agaiby, J, additional, Silverfield, J, additional, Sugimoto, D, additional, Lubin, B, additional, Alhaddad, M, additional, Lui, H, additional, Lakin, G, additional, Chokshi, S, additional, Donovan, D, additional, Felten, W, additional, Minton, S, additional, Kimmelstiel, C, additional, Kuvin, J, additional, Still, C, additional, Byars, W, additional, Talano, J, additional, Desai, V, additional, Bradley, AJ, additional, Baker, S, additional, Chane, M, additional, Mercado, A, additional, Baron, S, additional, Harris, B, additional, Mayer, N, additional, Concha, M, additional, Carr, K, additional, Chaykin, L, additional, Willis, J, additional, Clay, A, additional, Fenstad, E, additional, Furda, J, additional, Peterson, P, additional, Chang, M, additional, Aronne, L, additional, Jones, D, additional, Prashad, R, additional, Benson, M, additional, Stegemoller, R, additional, Longshaw, K, additional, Saleh, J, additional, Jennings, W, additional, Detweiler, R, additional, Viswanath, D, additional, Patel, R, additional, Lederman, S, additional, Weinstein, D, additional, Korabathina, R, additional, Singh, V, additional, Rosen, J, additional, Estevez, R, additional, Levin, P, additional, McNeill, R, additional, Kalen, V, additional, Reed, J, additional, Ashley, R, additional, Herman, L, additional, Tsai, Y, additional, Kayne, D, additional, White, A, additional, Hussain, I, additional, Tami, L, additional, Cohen, K, additional, Robinson, J, additional, Fuchs-Ertman, D, additional, Platt, G, additional, Belardo, L, additional, Reddy, R, additional, Rosendorff, C, additional, Saba, F, additional, Powell, S, additional, Anderson, K, additional, Abidi, M, additional, Rezkalla, S, additional, Paraschos, A, additional, Wilson, J, additional, Moursi, M, additional, Shah, A, additional, Nadar, V, additional, Stonesifer, L, additional, Bialow, M, additional, Cannon, K, additional, Ellison, W, additional, Stedman, M, additional, Brown, J, additional, Harper, W, additional, Lucas, KJ, additional, DiGiovanna, M, additional, Rodbard, H, additional, Biscoveanu, M, additional, Davis, C, additional, Hall, J, additional, Littlefield, R, additional, Gorman, T, additional, Kereiakes, D, additional, Chang, FM, additional, Tatu, H, additional, Cheung, D, additional, Kaine, J, additional, Knutson, T, additional, Logemann, T, additional, Pueblitz, G, additional, Bianco, J, additional, Henson, B, additional, Neustel, M, additional, Gelernt, M, additional, Nelson, W, additional, Moriarty, K, additional, Lefebvre, G, additional, Maw, K, additional, Rink, L, additional, Behn, P, additional, Studdard, H, additional, Argoud, G, additional, O'Connor, T, additional, Krichmar, P, additional, Raad, G, additional, Pereles-Ortiz, J, additional, Sorli, C, additional, Cohen, A, additional, Pettis, K, additional, Cavanaugh, B, additional, Phillips, C, additional, Wahlen, J, additional, Radin, D, additional, Rider, J, additional, Kosinski, E, additional, Leimbach, W, additional, Odhav, A, additional, Hakas, J, additional, Tan, A, additional, Howell, M, additional, Wombolt, D, additional, Fishman, N, additional, Shah, P, additional, Wylie, P, additional, Arauz-Pacheco, C, additional, Cavale, A, additional, George, A, additional, Kroll, R, additional, Krantzler, J, additional, Tahirkheli, N, additional, Jabro, M, additional, Newell, M, additional, Mullen, P, additional, Gencheff, N, additional, Meli, J, additional, Vora, K, additional, Kotek, L, additional, Pyzdrowski, K, additional, Paez, H, additional, Moran, J, additional, Tannenbaum, A, additional, Deck, K, additional, Busch, R, additional, Levinson, L, additional, Azizad, M, additional, Whitaker, J, additional, Fox, B, additional, Huffman, C, additional, Ashraf, M, additional, Diogo, J, additional, Kushner, R, additional, Tallet, J, additional, Channamsetty, V, additional, Suh, D, additional, Atieh, M, additional, Navas, J, additional, Young, V, additional, Shaw, S, additional, Dor, I, additional, Duffy, B, additional, Rubin, P, additional, Lewis, D, additional, Kaye, W, additional, Benton, R, additional, Burbano, J, additional, Hotchkiss, D, additional, Magno, A, additional, Alberton, A, additional, Collins, J, additional, Alvarado, O, additional, Stich, M, additional, Mahal, S, additional, Liu, J, additional, Hong, M, additional, Dy, J, additional, Block, B, additional, Lamantia, J, additional, Pritchard, J, additional, Davis, M, additional, Srivastava, S, additional, Bilazarian, S, additional, Rosario, R, additional, McCartney, M, additional, Blumberg, V, additional, Rajan, R, additional, Martin, E, additional, Wright, S, additional, Brinson, C, additional, Johnston, J, additional, Graves, M, additional, Dominguez, M, additional, McKenzie, W, additional, Abadier, R, additional, Tran, C, additional, Castello, R, additional, Morawski, E, additional, White, J, additional, Morris, F, additional, Perez, A, additional, Trueba, P, additional, Sanchez, M, additional, Andersen, J, additional, Kastelic, R, additional, Khan, J, additional, Rodriguez, H, additional, Izquierdo, W, additional, Matias, A, additional, Essandoh, L, additional, and Ince, C, additional
- Published
- 2018
- Full Text
- View/download PDF
9. Long-term safety and efficacy of breast biopsy markers in clinical practice.
- Author
-
Smith, Sharon, Taylor, Clayton R., Kanevsky, Estella, Povoski, Stephen P., and Hawley, Jeffrey R.
- Subjects
BREAST biopsy ,DRUG efficacy ,BIOMARKERS ,MEDICAL personnel ,MEDICATION safety ,MEDICAL records - Abstract
Objective: Percutaneous breast and axillary core biopsy followed by marker placement are integral parts of a breast imager's practice benefiting both patients and clinicians. Marker placement is the standard to facilitate future care. The purpose of this study is to characterize the safety and performance of MammoMARK, CorMARK, and HydroMARK biopsy markers by evaluating device-related adverse events, device deficiencies, and long-term safety. Methods: A retrospective review of three radiology practices identified patients who underwent image-guided breast or axillary biopsies followed by marker placement between 1 January 2012 and 1 January 2017. Medical records were reviewed with adverse events related to marker placement and use recorded. Results: 768 markers were placed with three (0.4%) events recorded. Two device deficiencies and one non-serious adverse event occurred in three patients. Device deficiency events involved user errors deploying the markers, one to inability to locate the marker on post-biopsy imaging, and the second to misplacement relative to biopsy target. One non-serious adverse event involved inability to locate/retain the marker in a surgically resected specimen. No serious adverse events were reported. Conclusion: Placement of breast biopsy markers is safe with minimal associated risks. Issues related to device malfunction, durability, reliability, safety, or performance were not reported. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
10. Cardiovascular Outcomes According to Urinary Albumin and Kidney Disease in Patients With Type 2 Diabetes at High Cardiovascular Risk
- Author
-
Scirica, Benjamin M., primary, Mosenzon, Ofri, additional, Bhatt, Deepak L., additional, Udell, Jacob, A., additional, Steg, Ph Gabriel, additional, McGuire, Darren K., additional, Im, KyungAh, additional, Kanevsky, Estella, additional, Stahre, Christina, additional, Sjöstrand, Mikaela, additional, Raz, Itamar, additional, and Braunwald, Eugene, additional
- Published
- 2018
- Full Text
- View/download PDF
11. Cognitive Function in a Randomized Trial of Evolocumab
- Author
-
Giugliano, Robert P., primary, Mach, François, additional, Zavitz, Kenton, additional, Kurtz, Christopher, additional, Im, Kyungah, additional, Kanevsky, Estella, additional, Schneider, Jingjing, additional, Wang, Huei, additional, Keech, Anthony, additional, Pedersen, Terje R., additional, Sabatine, Marc S., additional, Sever, Peter S., additional, Robinson, Jennifer G., additional, Honarpour, Narimon, additional, Wasserman, Scott M., additional, and Ott, Brian R., additional
- Published
- 2017
- Full Text
- View/download PDF
12. Hypoglycaemia manifestations and recurrent events: Lessons from the SAVOR-TIMI 53 outcome study
- Author
-
Cahn, Avivit, primary, Mosenzon, Ofri, additional, Bhatt, Deepak L., additional, Leibowitz, Gil, additional, Yanuv, Ilan, additional, Rozenberg, Aliza, additional, Iqbal, Nayyar, additional, Hirshberg, Boaz, additional, Stahre, Christina, additional, Im, KyungAh, additional, Kanevsky, Estella, additional, and Raz, Itamar, additional
- Published
- 2017
- Full Text
- View/download PDF
13. Predisposing Factors for Any and Major Hypoglycemia With Saxagliptin Versus Placebo and Overall: Analysis From the SAVOR-TIMI 53 Trial
- Author
-
Cahn, Avivit, primary, Raz, Itamar, additional, Mosenzon, Ofri, additional, Leibowitz, Gil, additional, Yanuv, Ilan, additional, Rozenberg, Aliza, additional, Iqbal, Nayyar, additional, Hirshberg, Boaz, additional, Sjostrand, Mikaela, additional, Stahre, Christina, additional, Im, KyungAh, additional, Kanevsky, Estella, additional, Scirica, Benjamin M., additional, Bhatt, Deepak L., additional, and Braunwald, Eugene, additional
- Published
- 2016
- Full Text
- View/download PDF
14. CLINICAL FACTORS ASSOCIATED WITH SUDDEN CARDIAC DEATH IN TYPE 2 DIABETES: INSIGHTS FROM THE SAVOR-TIMI 53 TRIAL
- Author
-
Cavallari, Ilaria, primary, Patel, Ravi, additional, Bhatt, Deepak, additional, Steg, Philippe, additional, Leiter, Lawrence, additional, McGuire, Darren, additional, Mosenzon, Ofri, additional, Kanevsky, Estella, additional, Im, Kyungah, additional, Raz, Itamar, additional, Braunwald, Eugene, additional, and Scirica, Benjamin, additional
- Published
- 2016
- Full Text
- View/download PDF
15. 746
- Author
-
Wong, Jackson, primary, Kanevsky, Estella, additional, Agus, Michael, additional, Graham, Dionne, additional, Bartlett, Joshua, additional, and Melendez, Elliot, additional
- Published
- 2014
- Full Text
- View/download PDF
16. Regional Implementation of a Pediatric Cardiology Chest Pain Guideline Using SCAMPs Methodology
- Author
-
Angoff, Gerald H., primary, Kane, David A., additional, Giddins, Niels, additional, Paris, Yvonne M., additional, Moran, Adrian M., additional, Tantengco, Victoria, additional, Rotondo, Kathleen M., additional, Arnold, Lucy, additional, Toro-Salazar, Olga H., additional, Gauthier, Naomi S., additional, Kanevsky, Estella, additional, Renaud, Ashley, additional, Geggel, Robert L., additional, Brown, David W., additional, and Fulton, David R., additional
- Published
- 2013
- Full Text
- View/download PDF
17. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk.
- Author
-
O'Donoghue ML, Fazio S, Giugliano RP, Stroes ESG, Kanevsky E, Gouni-Berthold I, Im K, Lira Pineda A, Wasserman SM, Češka R, Ezhov MV, Jukema JW, Jensen HK, Tokgözoğlu SL, Mach F, Huber K, Sever PS, Keech AC, Pedersen TR, and Sabatine MS
- Subjects
- Adult, Aged, Aged, 80 and over, Atherosclerosis pathology, Cholesterol, LDL blood, Double-Blind Method, Female, Humans, Male, Middle Aged, Placebo Effect, Proportional Hazards Models, Proprotein Convertase 9 metabolism, Risk Factors, Treatment Outcome, Antibodies, Monoclonal, Humanized therapeutic use, Anticholesteremic Agents therapeutic use, Atherosclerosis drug therapy, Lipoprotein(a) blood, Proprotein Convertase 9 immunology
- Abstract
Background: Lipoprotein(a) [Lp(a)] may play a causal role in atherosclerosis. PCSK9 (proprotein convertase subtilisin/kexin 9) inhibitors have been shown to significantly reduce plasma Lp(a) concentration. However, the relationship between Lp(a) levels, PCSK9 inhibition, and cardiovascular risk reduction remains undefined., Methods: Lp(a) was measured in 25 096 patients in the FOURIER trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk), a randomized trial of evolocumab versus placebo in patients with established atherosclerotic cardiovascular disease (median follow-up, 2.2 years). Cox models were used to assess the independent prognostic value of Lp(a) and the efficacy of evolocumab for coronary risk reduction by baseline Lp(a) concentration., Results: The median (interquartile range) baseline Lp(a) concentration was 37 (13-165) nmol/L. In the placebo arm, patients with baseline Lp(a) in the highest quartile had a higher risk of coronary heart disease death, myocardial infarction, or urgent revascularization (adjusted hazard ratio quartile 4: quartile 1, 1.22; 95% CI, 1.01-1.48) independent of low-density lipoprotein cholesterol. At 48 weeks, evolocumab significantly reduced Lp(a) by a median (interquartile range) of 26.9% (6.2%-46.7%). The percent change in Lp(a) and low-density lipoprotein cholesterol at 48 weeks in patients taking evolocumab was moderately positively correlated ( r=0.37; 95% CI, 0.36-0.39; P<0.001). Evolocumab reduced the risk of coronary heart disease death, myocardial infarction, or urgent revascularization by 23% (hazard ratio, 0.77; 95% CI, 0.67-0.88) in patients with a baseline Lp(a) >median, and by 7% (hazard ratio, 0.93; 95% CI, 0.80-1.08; P interaction=0.07) in those ≤median. Coupled with the higher baseline risk, the absolute risk reductions, and number needed to treat over 3 years were 2.49% and 40 versus 0.95% and 105, respectively., Conclusions: Higher levels of Lp(a) are associated with an increased risk of cardiovascular events in patients with established cardiovascular disease irrespective of low-density lipoprotein cholesterol. Evolocumab significantly reduced Lp(a) levels, and patients with higher baseline Lp(a) levels experienced greater absolute reductions in Lp(a) and tended to derive greater coronary benefit from PCSK9 inhibition., Clinical Trial Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT01764633.
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.